\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ is\\ unremarkable\\.\\ \ \(1\)\
\-\ labs\\:\ \(4\)\
\-\ hemoglobin\\/hematocrit\\:\\ 13\\.0\\/38\\.0\ \(0\)\
\-\ wbc\\:\\ 7\\.3\ \(0\)\
\-\ platelets\\:\\ 291\ \(0\)\
\-\ sodium\\:\\ 139\ \(0\)\
\-\ potassium\\:\\ 3\\.9\ \(0\)\
\-\ chloride\\:\\ 103\ \(0\)\
\-\ bicarbonate\\:\\ 25\\.7\ \(0\)\
\-\ glucose\\:\\ 103\ \(0\)\
\-\ creatinine\\:\\ 0\\.3\ \(0\)\
\-\ bun\\:\\ 16\ \(0\)\
\-\ c24\\:0\\ tetracosanoic\\ acid\\ \\(high\\)\\ 101\\.96\\ \ \(0\)\
\-\ \\\\-\\-reference\\ range\\:\\ 24\\.25\\ to\\ 77\\.75\\\\ unit\\:\\ umol\\/l\\ \ \(0\)\
\-\ c26\\:0\\ hexacocanoic\\ acid\\ \\(high\\)\\ 2\\.81\\\ \(0\)\
\-\ \\-reference\\ range\\:\\ 0\\.17\\ to\\ 0\\.73\\\\ unit\\:\\ umol\\/l\ \(0\)\
\-\ c24\\:0\\/c22\\:0\\ \\(high\\)\\ 1\\.86\\\\ \ \(0\)\
\-\ \\-\\ reference\\ range\\:\\ 0\\.64\\ to\\ 1\\.02\\ \ \(0\)\
\-\ c26\\:0\\/c22\\:0\\ \\(high\\)\\ 0\\.051\\\\ \ \(0\)\
\-\ \\-reference\\ range\\:\\ 0\\.003\\ to\\ 0\\.015\ \(0\)\
\-\ treatment\\:\\ current\\ treatment\\ modalities\\ include\\ dietary\\ therapy\\ involving\\ a\\ low\\-fat\\ diet\\ and\\ consumption\\ of\\ lorenzo\\â\\€\\™s\\ oil\\,\\ lovastatin\\ therapy\\,\\ bone\\ marrow\\ transplants\\,\\ and\\ iv\\ immunoglobulin\\ therapy\\.\ \(0\)\
\-\ follow\\ up\\:\\ genetic\\ counseling\\ for\\ family\ \(0\)\
\-\ head\\ ct\\ without\\ iv\\ contrast\\:\ \(0\)\
\-\ focal\\ low\\-attenuation\\ in\\ the\\ splenium\\Â\\ of\\Â\\ the\\Â\\ corpus\\Â\\ callosum\\,\\Â\\ with\\\\ associated\\Â\\ vasogenic\\Â\\ edema\\Â\\ extending\\Â\\ into\\Â\\ the\\Â\\ cerebral\\Â\\ white\\ matter\\ \\bilaterally\\.\\ lateral\\ ventricles\\ appear\\ borderline\\ enlarged\\,\\ r\\>l\ \(0\)\
\-\ head\\ mri\\ without\\ and\\ with\\ iv\\ contrast\\:\ \(0\)\
\-\ there\\Â\\ is\\Â\\ a\\ symmetric\\Â\\ and\\Â\\ confluent\\Â\\ signal\\Â\\ abnormality\\ involving\\Â\\ the\\Â\\ \\ splenium\\Â\\ of\\Â\\ the\\Â\\ corpus\\Â\\ callosum\\,\\Â\\ bilateral\\Â\\ peritrigonal\\ white\\Â\\ \\ matter\\,\\Â\\ and\\Â\\ corticospinal\\Â\\ tracts\\;\\ hyper\\-intense\\Â\\ on\\Â\\ t2\\-weighted\\ images\\Â\\ and\\Â\\ hypo\\-intense\\Â\\ on\\Â\\ t1\\ weighted\\Â\\ images\\.\\Â\\ \\ there\\Â\\ is\\Â\\ linear\\Â\\ peripheral\\Â\\ enhancment\\Â\\ just\\ beneath\\Â\\ the\\Â\\ leading\\Â\\ edge\\Â\\ of\\ the\\ abnormal\\ areas\\Â\\ including\\Â\\ the\\ peritrigonal\\Â\\ white\\Â\\ matter\\Â\\ and\\Â\\ corticospinal\\Â\\ tracts\\;\\Â\\ this\\Â\\ intermediatezone\\Â\\ enhancement\\Â\\ is\\Â\\ \\ typical\\Â\\ of\\ x\\-linked\\Â\\ adrenal\\ leukodystrophy\\.\\Â\\ mild\\ diffusion\\ restriction\\Â\\ \\ is\\Â\\ also\\Â\\ seen\\Â\\ in\\Â\\ an\\Â\\ identical\\ distribution\\ to\\ the\\ linear\\Â\\ enhancement\\,\\Â\\ \\ which\\Â\\ has\\Â\\ also\\Â\\ been\\Â\\ described\\Â\\ with\\Â\\ x\\-linked\\Â\\ ald\\Â\\ and\\ has\\Â\\ been\\Â\\ \\ attributed\\ to\\ active\\Â\\ demyelination\\.\\ on\\Â\\ t2\\-weighted\\Â\\ images\\,\\ this\\Â\\ thin\\Â\\ \\ intermediate\\ zone\\ is\\Â\\ about\\Â\\ iso\\-intense\\Â\\ to\\Â\\ normal\\Â\\ white\\ matter\\,\\ which\\Â\\ also\\Â\\ is\\ a\\ typical\\Â\\ finding\\.\\Â\\ no\\Â\\ abnormalities\\ are\\ identified\\ in\\Â\\ \\ the\\ frontal\\ white\\ matter\\.\\ the\\ ventricles\\Â\\ appear\\Â\\ normal\\ in\\Â\\ size\\Â\\ and\\ shape\\.\ \(0\)\
\-\ x\\-linked\\ adrenoleukodystrophy\ \(0\)\
\-\ leukoencephalopathy\ \(7\)\
\-\ leukodystrophy\ \(9\)\
\-\ this\\ is\\ a\\ 7\\ year\\ old\\ boy\\ who\\ presents\\ to\\ the\\ children\\'s\\ ed\\ with\\ dizziness\\,\\ ataxia\\,\\ weakness\\,\\ vomiting\\,\\ and\\ leg\\ twitching\\.\\ the\\ patient\\ had\\ been\\ at\\ a\\ wrestling\\ match\\ doing\\ warm\\ up\\ exercises\\ at\\ the\\ time\\ of\\ the\\ onset\\ of\\ symptoms\\.\\ \\ he\\ has\\ a\\ history\\ of\\ tics\\ and\\ nystagmus\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ reference\\:\\ 0\\.2002016856388416\ \(0\)\
\-\ matter\\:\\ 0\\.1947383842902051\ \(0\)\
\-\ white\\:\\ 0\\.1687419259855678\ \(0\)\
\-\ peritrigonal\\:\\ 0\\.1636051305780204\ \(0\)\
\-\ range\\:\\ 0\\.15877492113714037\ \(0\)\
\-\ the\\:\\ 0\\.15309900450941147\ \(0\)\
\-\ corticospinal\\:\\ 0\\.14113782362405639\ \(0\)\
\-\ leukodystrophy\\:\\ 0\\.14113782362405639\ \(0\)\
\-\ splenium\\:\\ 0\\.12746944826346154\ \(0\)\
\-\ tracts\\:\\ 0\\.11980357999607022\ \(0\)\
\-\ high\\:\\ 0\\.11628490180085835\ \(0\)\
\-\ and\\:\\ 0\\.1162684008915926\ \(0\)\
\-\ weighted\\:\\ 0\\.1144646603236897\ \(0\)\
\-\ 103\\:\\ 0\\.11279370378159267\ \(0\)\
\-\ is\\:\\ 0\\.11206573445365417\ \(0\)\
\-\ iv\\:\\ 0\\.10964633287385779\ \(0\)\
\-\ unit\\:\\ 0\\.1094362137478067\ \(0\)\
\-\ acid\\:\\ 0\\.10623947355854575\ \(0\)\
\-\ to\\:\\ 0\\.10230242263734385\ \(0\)\
\-\ callosum\\:\\ 0\\.09636075864368321\ \(0\)\
\-\ corpus\\:\\ 0\\.09326765970168482\ \(0\)\
\-\ ventricles\\:\\ 0\\.08987987905151705\ \(0\)\
\-\ been\\:\\ 0\\.08940452767146094\ \(0\)\
\-\ therapy\\:\\ 0\\.08816975801155626\ \(0\)\
\-\ linear\\:\\ 0\\.08241324606438591\ \(0\)\
\-\ tetracosanoic\\:\\ 0\\.0818025652890102\ \(0\)\
\-\ hexacocanoic\\:\\ 0\\.0818025652890102\ \(0\)\
\-\ lorenzo\\:\\ 0\\.0818025652890102\ \(0\)\
\-\ lovastatin\\:\\ 0\\.0818025652890102\ \(0\)\
\-\ intermediatezone\\:\\ 0\\.0818025652890102\ \(0\)\
\-\ ald\\:\\ 0\\.0818025652890102\ \(0\)\
\-\ tics\\:\\ 0\\.0818025652890102\ \(0\)\
\-\ appear\\:\\ 0\\.08057222549835061\ \(0\)\
\-\ of\\:\\ 0\\.08008115440607398\ \(0\)\
\-\ typical\\:\\ 0\\.07906285072479811\ \(0\)\
\-\ 291\\:\\ 0\\.07816671825645881\ \(0\)\
\-\ adrenoleukodystrophy\\:\\ 0\\.07558704373323691\ \(0\)\
\-\ also\\:\\ 0\\.07218075867708083\ \(0\)\
\-\ involving\\:\\ 0\\.071657617664077\ \(0\)\
\-\ images\\:\\ 0\\.07098307985235142\ \(0\)\
\-\ bicarbonate\\:\\ 0\\.07056891181202819\ \(0\)\
\-\ has\\:\\ 0\\.07009369946764436\ \(0\)\
\-\ twitching\\:\\ 0\\.0693715221774636\ \(0\)\
\-\ wrestling\\:\\ 0\\.0693715221774636\ \(0\)\
\-\ match\\:\\ 0\\.0693715221774636\ \(0\)\
\-\ transplants\\:\\ 0\\.0683153496681341\ \(0\)\
\-\ enhancment\\:\\ 0\\.0683153496681341\ \(0\)\
\-\ consumption\\:\\ 0\\.06737057116428218\ \(0\)\
\-\ immunoglobulin\\:\\ 0\\.0657356751449122\ \(0\)\
\-\ chloride\\:\\ 0\\.06435339025625489\ \(0\)\
\-\ oil\\:\\ 0\\.06373472413173077\ \(0\)\
\-\ 139\\:\\ 0\\.0631560006216903\ \(0\)\
\-\ beneath\\:\\ 0\\.0631560006216903\ \(0\)\
\-\ potassium\\:\\ 0\\.0620998281123608\ \(0\)\
\-\ counseling\\:\\ 0\\.0620998281123608\ \(0\)\
\-\ leukoencephalopathy\\:\\ 0\\.06161500181761242\ \(0\)\
\-\ head\\:\\ 0\\.06101589080206097\ \(0\)\
\-\ identical\\:\\ 0\\.06071754322370349\ \(0\)\
\-\ restriction\\:\\ 0\\.06030039349264636\ \(0\)\
\-\ dietary\\:\\ 0\\.05990178999803511\ \(0\)\
\-\ sodium\\:\\ 0\\.0595201535891389\ \(0\)\
\-\ demyelination\\:\\ 0\\.0595201535891389\ \(0\)\
\-\ confluent\\:\\ 0\\.059154098595327435\ \(0\)\
\-\ enhancement\\:\\ 0\\.05888395626288505\ \(0\)\
\-\ platelets\\:\\ 0\\.057823201252031046\ \(0\)\
\-\ borderline\\:\\ 0\\.057823201252031046\ \(0\)\
\-\ attributed\\:\\ 0\\.05722517288604133\ \(0\)\
\-\ warm\\:\\ 0\\.05722517288604133\ \(0\)\
\-\ nystagmus\\:\\ 0\\.056940479065916996\ \(0\)\
\-\ exercises\\:\\ 0\\.05639685189079634\ \(0\)\
\-\ diet\\:\\ 0\\.055638617156921\ \(0\)\
\-\ modalities\\:\\ 0\\.05471810687390335\ \(0\)\
\-\ doing\\:\\ 0\\.054291021294599694\ \(0\)\
\-\ without\\:\\ 0\\.05396110564468081\ \(0\)\
\-\ this\\:\\ 0\\.05272984641000102\ \(0\)\
\-\ intermediate\\:\\ 0\\.052248459524036096\ \(0\)\
\-\ creatinine\\:\\ 0\\.05208392092369163\ \(0\)\
\-\ edge\\:\\ 0\\.05160767969625774\ \(0\)\
\-\ in\\:\\ 0\\.05089944516249922\ \(0\)\
\-\ up\\:\\ 0\\.05060555120036842\ \(0\)\
\-\ genetic\\:\\ 0\\.050449024904321654\ \(0\)\
\-\ vasogenic\\:\\ 0\\.0503141787222498\ \(0\)\
\-\ dizziness\\:\\ 0\\.04992139613152685\ \(0\)\
\-\ contrast\\:\\ 0\\.04970704896538255\ \(0\)\
\-\ ataxia\\:\\ 0\\.049668785000814196\ \(0\)\
\-\ glucose\\:\\ 0\\.049423095601147694\ \(0\)\
\-\ zone\\:\\ 0\\.049423095601147694\ \(0\)\
\-\ bun\\:\\ 0\\.04930273000700273\ \(0\)\
\-\ treatment\\:\\ 0\\.04873245514310895\ \(0\)\
\-\ shape\\:\\ 0\\.048502585318130044\ \(0\)\
\-\ adrenal\\:\\ 0\\.04737380429771662\ \(0\)\
\-\ which\\:\\ 0\\.04651829493811695\ \(0\)\
\-\ on\\:\\ 0\\.0463459955940299\ \(0\)\
\-\ leading\\:\\ 0\\.045469795873307066\ \(0\)\
\-\ current\\:\\ 0\\.04479412977449472\ \(0\)\
\-\ symmetric\\:\\ 0\\.0438348998539371\ \(0\)\
\-\ distribution\\:\\ 0\\.04339120712730301\ \(0\)\
\-\ diffusion\\:\\ 0\\.043087208451229424\ \(0\)\
\-\ marrow\\:\\ 0\\.04250848494118896\ \(0\)\
\-\ children\\:\\ 0\\.04191226464096301\ \(0\)\
\-\ normal\\:\\ 0\\.041769721390158304\ \(0\)\
\-\ described\\:\\ 0\\.04150226856176119\ \(0\)\
\-\ just\\:\\ 0\\.040920414626789275\ \(0\)\
\-\ ed\\:\\ 0\\.040920414626789275\ \(0\)\
\-\ there\\:\\ 0\\.04070613631120284\ \(0\)\
\-\ family\\:\\ 0\\.04024247712961336\ \(0\)\
\-\ with\\:\\ 0\\.04006450143837466\ \(0\)\
\-\ 16\\:\\ 0\\.03985902716987165\ \(0\)\
\-\ thin\\:\\ 0\\.03981741641248949\ \(0\)\
\-\ at\\:\\ 0\\.03864122375671797\ \(0\)\
\-\ leg\\:\\ 0\\.03861483898366678\ \(0\)\
\-\ about\\:\\ 0\\.0382939143985971\ \(0\)\
\-\ active\\:\\ 0\\.037984079664963095\ \(0\)\
\-\ vomiting\\:\\ 0\\.03784973854369991\ \(0\)\
\-\ weakness\\:\\ 0\\.03733163910455968\ \(0\)\
\-\ abnormality\\:\\ 0\\.03720666004835576\ \(0\)\
\-\ abnormalities\\:\\ 0\\.037052846635174864\ \(0\)\
\-\ including\\:\\ 0\\.036606630097061964\ \(0\)\
\-\ peripheral\\:\\ 0\\.03657765720553999\ \(0\)\
\-\ identified\\:\\ 0\\.036264984884948386\ \(0\)\
\-\ wbc\\:\\ 0\\.03615393576138179\ \(0\)\
\-\ labs\\:\\ 0\\.03543830726955315\ \(0\)\
\-\ cerebral\\:\\ 0\\.03543830726955315\ \(0\)\
\-\ boy\\:\\ 0\\.03499110147641966\ \(0\)\
\-\ enlarged\\:\\ 0\\.03487073588227469\ \(0\)\
\-\ areas\\:\\ 0\\.03472839793932362\ \(0\)\
\-\ extending\\:\\ 0\\.034681449653414534\ \(0\)\
\-\ size\\:\\ 0\\.034634745890936305\ \(0\)\
\-\ unremarkable\\:\\ 0\\.034292012372234226\ \(0\)\
\-\ bilaterally\\:\\ 0\\.03411444019092503\ \(0\)\
\-\ finding\\:\\ 0\\.03362267609921544\ \(0\)\
\-\ frontal\\:\\ 0\\.032922546788297785\ \(0\)\
\-\ onset\\:\\ 0\\.032845904423221745\ \(0\)\
\-\ t1\\:\\ 0\\.03187065145630912\ \(0\)\
\-\ abnormal\\:\\ 0\\.03073120428908628\ \(0\)\
\-\ focal\\:\\ 0\\.030596583046550246\ \(0\)\
\-\ edema\\:\\ 0\\.030507945401030485\ \(0\)\
\-\ include\\:\\ 0\\.0304347441608506\ \(0\)\
\-\ time\\:\\ 0\\.030318851082414743\ \(0\)\
\-\ he\\:\\ 0\\.030290110345871358\ \(0\)\
\-\ signal\\:\\ 0\\.02899639523466803\ \(0\)\
\-\ mild\\:\\ 0\\.02899639523466803\ \(0\)\
\-\ who\\:\\ 0\\.02893451022627736\ \(0\)\
\-\ symptoms\\:\\ 0\\.0279872651835225\ \(0\)\
\-\ bone\\:\\ 0\\.027909914469914057\ \(0\)\
\-\ physical\\:\\ 0\\.02773557892539331\ \(0\)\
\-\ follow\\:\\ 0\\.027575161371300366\ \(0\)\
\-\ bilateral\\:\\ 0\\.027490764493003205\ \(0\)\
\-\ into\\:\\ 0\\.027191317023524904\ \(0\)\
\-\ associated\\:\\ 0\\.026960736013998843\ \(0\)\
\-\ mri\\:\\ 0\\.02625669954299823\ \(0\)\
\-\ exam\\:\\ 0\\.025749747683317954\ \(0\)\
\-\ had\\:\\ 0\\.02548561441529875\ \(0\)\
\-\ lateral\\:\\ 0\\.02538542228776145\ \(0\)\
\-\ presents\\:\\ 0\\.024606566303096933\ \(0\)\
\-\ seen\\:\\ 0\\.02408176534280208\ \(0\)\
\-\ an\\:\\ 0\\.01956020519581263\ \(0\)\
\-\ history\\:\\ 0\\.01954287745684577\ \(0\)\
\-\ ct\\:\\ 0\\.01947389940806173\ \(0\)\
\-\ are\\:\\ 0\\.019409710858207026\ \(0\)\
\-\ patient\\:\\ 0\\.016637051913736538\ \(0\)\
\-\ no\\:\\ 0\\.01663392258125842\ \(0\)\
\-\ year\\:\\ 0\\.015763920107428674\ \(0\)\
\-\ for\\:\\ 0\\.015503661396925435\ \(0\)\
\-\ old\\:\\ 0\\.015138820119496207\ \(0\)\
